Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N B Modi

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of Cardiovascular Pharmacology|September 11, 1998
Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beaglesN B Modi, Y S Lin, T Reynolds, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|March 28, 1998
Determination of Ro 48-3656 in rat plasma by reversed-phase high-performance liquid chromatography. Comparison of 1.5-microm nonporous silica to 3.5-microm porous silica analytical columnsB D Paasch, Y S Lin, S Porter, et al.
Journal of Cardiovascular Pharmacology|June 1, 1995
Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogsN B Modi, S A Baughman, B D Paasch, et al.
The Journal of Laboratory and Clinical Medicine|March 1, 1992
A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studiesJ A Widness, R L Schmidt, P Veng-Pedersen, et al.
Pharmaceutical Research|February 1, 1994
Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approachN B Modi, P Veng-Pedersen, D E Wurster, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarctionN B Modi, S Eppler, J Breed, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1992
Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheepJ A Widness, P Veng-Pedersen, N B Modi, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beaglesN B Modi, T Reynolds, S A Baughman, et al.
Endocrinology|April 1, 1994
The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in ratsT F Zioncheck, L Richardson, G G DeGuzman, et al.
Journal of Pharmaceutical Sciences|August 1, 1993
A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemiaP Veng-Pedersen, N B Modi, J A Widness, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Cardiovascular Pharmacology|September 11, 1998
Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beaglesN B Modi, Y S Lin, T Reynolds, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|March 28, 1998
Determination of Ro 48-3656 in rat plasma by reversed-phase high-performance liquid chromatography. Comparison of 1.5-microm nonporous silica to 3.5-microm porous silica analytical columnsB D Paasch, Y S Lin, S Porter, et al.
Journal of Cardiovascular Pharmacology|June 1, 1995
Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogsN B Modi, S A Baughman, B D Paasch, et al.
The Journal of Laboratory and Clinical Medicine|March 1, 1992
A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studiesJ A Widness, R L Schmidt, P Veng-Pedersen, et al.
Pharmaceutical Research|February 1, 1994
Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approachN B Modi, P Veng-Pedersen, D E Wurster, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarctionN B Modi, S Eppler, J Breed, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1992
Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheepJ A Widness, P Veng-Pedersen, N B Modi, et al.
Journal of Cardiovascular Pharmacology|January 1, 1996
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beaglesN B Modi, T Reynolds, S A Baughman, et al.
Endocrinology|April 1, 1994
The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in ratsT F Zioncheck, L Richardson, G G DeGuzman, et al.
Journal of Pharmaceutical Sciences|August 1, 1993
A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemiaP Veng-Pedersen, N B Modi, J A Widness, et al.
Pageof 4